YJYi Jiang

Yi Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Recognitions

Top Cited Scholar (2026)

Yi Jiang has a total of 439 co-authors. Here are the top co-authors by number of shared publications:

  • H. Eric Xu

    CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    71 shared publications
  • Wanchao Yin

    Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.

    23 shared publications
  • Hualiang Jiang

    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    17 shared publications
  • Ming-Wei Wang

    Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    17 shared publications
  • Xinheng He

    The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    17 shared publications
  • Qingning Yuan

    Lingang Laboratory, Shanghai, China

    15 shared publications

Latest Publications

  • Primate-specific regulation of the human glycosphingolipid gatekeeper UGCG

    by Canrong Wu, Sanshan Jin, Jiuyin Xu, James Jiqi Wang, Xiaoqi Guo, Yunhai Li, Zhenyu Cao, Mengting Jiang, Qingning Yuan, Wen Hu, et al.


  • Open Access

    Structural and functional basis of antinociceptive action of χ-conotoxin AoIA at the noradrenaline transporter

    by Oliver J. V. Belleza, Heng Zhang, Helmut Schmidhammer, Tye I. Gonzalez, Cosmin I. Ciotu, Nataša Tomašević, Carlo Martin M. Ocampo, Jomari C. Fernando, Johannes Koehbach, Paula Schwarz, et al.

    The χ-conotoxins are venom-derived peptides that specifically target the noradrenaline transporter (also known as norepinephrine transporter, NET). Regulation of noradrenergic signaling by NET affects neurophysiological processes, including pain. Therefore, the χ-conotoxin MrIA and its synthetic analogs have been previously investigated for their analgesic activity. Here we describe the synthesis and pharmacological characterization of χ-AoIA, a peptide that selectively inhibits NET with a higher potency compared to MrIA in in vitro radiotracer flux assays. Furthermore, we resolved the structure of the human NET:χ-AoIA complex by cryogenic electron microscopy, which revealed an atypical binding mode consisting of both the central binding site and the outer vestibule of the transporter. Lastly, χ-AoIA displays antinociceptive efficacy in a model of inflammatory pain after subcutaneous administration in mice. Our results demonstrate the efficacy of χ-AoIA as a highly selective ligand of NET and provide a mechanistic basis for its potential development as a nonopioid analgesic.

  • Open Access

    Author Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor

    by Tianwei Zhang, Hongli Liu, Chongzhao You, Yixiao Zhang, Youwei Xu, Benxun Pan, Canrong Wu, Sanshan Jin, Yu-Ling Yin, Kai Wu, et al.

  • Open Access

    Structural insights into antagonist recognition by the vasopressin V2 receptor

    by Tianwei Zhang, Hongli Liu, Chongzhao You, Yixiao Zhang, Youwei Xu, Benxun Pan, Canrong Wu, Sanshan Jin, Yu-Ling Yin, Kai Wu, et al.

    The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.


  • Unveiling conformation-selective regulation of the norepinephrine transporter

    by Heng Zhang, Tianwei Zhang, Dingyan Wang, Antao Dai, Jianhang Mao, Qihui Chen, Tianyuan Du, Xue Lu, Yongxin Hao, Chao Zhang, et al.


  • Decoding ligand recognition and constitutive activation of histamine H3 and H4 receptors

    by San-Shan Jin, Heng Zhang, Jia-Hui Yan, Can-Rong Wu, Xiao-Qing Cai, Kai Wu, Ming-Wei Wang, H. Eric Xu, De-Hua Yang, Yi Jiang

    Histamine H3 receptor (H3R) and H4 receptor (H4R) are key members of the histamine receptor family, with H3R as a potential target for narcolepsy treatments and H4R as a candidate for next-generation antihistamines for inflammatory and allergic diseases. Although progress has been made in understanding the structure of histamine receptors, the detailed mechanisms of ligand recognition and receptor antagonism for H3R and H4R remain unclear. In this study, using cryo-electron microscopy, we present an inactive structure of H4R bound to a selective antagonist, adriforant, and two Gi-coupled structures of H3R and H4R in complex with histamine. Our structural and mutagenesis analyses provide insights into the selective binding of adriforant to H4R and the recognition of histamine across histamine receptors. Our findings also uncovered distinct antagonistic mechanisms for H3R and H4R and identified the role of aromatic amino acids on extracellular loop 2 in modulating the constitutive activity of H3R and H4R. These findings advance our knowledge of the functional modulation of histamine receptors, providing a foundation for the development of targeted therapeutics for neurological and immune-related disorders.


  • Open Access

    Structural basis of peptide recognition and modulation for neuropeptide FF receptors

    by Xinzhu Li, Heng Zhang, Wen Hu, Kai Wu, Shuai Li, Sanshan Jin, Yuling Yin, Qingning Yuan, H. Eric Xu, Benxun Pan, et al.


  • Open Access

    Molecular mechanism of pH sensing and activation in GPR4 reveals proton-mediated GPCR signaling

    by Chongzhao You, Shimeng Guo, Tianwei Zhang, Xinheng He, Tianyu Gao, Wenwen Xin, Zining Zhu, Yujie Lu, Youwei Xu, Zhen Li, et al.

    Maintaining pH homeostasis is critical for cellular function across all living organisms. Proton-sensing G protein-coupled receptors (GPCRs), particularly GPR4, play a pivotal role in cellular responses to pH changes. Yet, the molecular mechanisms underlying their proton sensing and activation remain incompletely understood. Here we present high-resolution cryo-electron microscopy structures of GPR4 in complex with G proteins under physiological and acidic pH conditions. Our structures reveal an intricate proton-sensing mechanism driven by a sophisticated histidine network in the receptor’s extracellular domain. Upon protonation of key histidines under acidic conditions, a remarkable conformational cascade is initiated, propagating from the extracellular region to the intracellular G protein-coupling interface. This dynamic process involves precise transmembrane helix rearrangements and conformational shifts of conserved motifs, mediated by strategically positioned water molecules. Notably, we discovered a bound bioactive lipid, lysophosphatidylcholine, which has positive allosteric effects on GPR4 activation. These findings provide a comprehensive framework for understanding proton sensing in GPCRs and the interplay between pH sensing and lipid regulation, offering insights into cellular pH homeostasis and potential therapies for pH-related disorders.


  • Open Access

    Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs

    by Canrong Wu, Chao Zhang, Sanshan Jin, James Jiqi Wang, Antao Dai, Jiuyin Xu, Heng Zhang, Xuemei Yang, Xinheng He, Qingning Yuan, et al.

    Gout, a common and painful disease, stems from hyperuricemia, where elevated blood urate levels lead to urate crystal formation in joints and kidneys. The human urate transporter 1 (hURAT1) plays a critical role in urate homeostasis by facilitating urate reabsorption in the renal proximal tubule, making it a key target for gout therapy. Pharmacological inhibition of hURAT1 with drugs such as dotinurad, benzbromarone, lesinurad, and verinurad promotes urate excretion and alleviates gout symptoms. Here, we present cryo-electron microscopy structures of native hURAT1 bound with these anti-gout drugs in the inward-open state, and with urate in inward-open, outward-open, and occluded states. Complemented by mutagenesis and cell-based assays, these structures reveal the mechanisms of urate reabsorption and hURAT1 inhibition. Our findings elucidate the molecular basis of urate transport and anti-gout medication action and provide a structural framework for the rational design of next-generation therapies for hyperuricemia and gout.


  • Open Access

    Decoding the structural basis of ligand recognition and biased signaling in the motilin receptor

    by Chongzhao You, Mengting Jiang, Tianyu Gao, Zining Zhu, Xinheng He, Youwei Xu, Yuan Gao, Yi Jiang, H. Eric Xu